(ORIC) Oric Pharmaceuticals - Overview
Stock: Kinase Inhibitor, AR Pathway, CD73 Inhibitor, Breast Cancer
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 79.1% |
| Relative Tail Risk | -7.31% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.12 |
| Alpha | -35.65 |
| Character TTM | |
|---|---|
| Beta | 1.356 |
| Beta Downside | 1.452 |
| Drawdowns 3y | |
|---|---|
| Max DD | 73.46% |
| CAGR/Max DD | 0.38 |
Description: ORIC Oric Pharmaceuticals January 21, 2026
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) is a clinical-stage biotech focused on small-molecule therapies that overcome resistance mechanisms in solid tumors. Its lead candidates are ORIC-114, an oral irreversible inhibitor targeting EGFR and HER2 exon 20 insertion mutations (currently in a Phase 1b trial), and ORIC-944, an allosteric PRC2 inhibitor being evaluated for prostate cancer in Phase 1b studies. The pipeline also includes ORIC-533 (a CD73 inhibitor) and ORIC-613 (a breast-cancer resistance modulator), each at pre-clinical or early-clinical stages.
As of the latest 10-Q filing (Q4 2023), ORIC reported approximately $150 million of cash and marketable securities, giving it roughly 18 months of runway at its current burn rate of ~$30 million per year. The company’s market capitalization hovers near $300 million, and R&D expense has risen 42 % year-over-year, reflecting the acceleration of Phase 1b programs and partnership activities.
Key market drivers include the unmet clinical need for EGFR exon 20-mutated non-small-cell lung cancer, which represents roughly 10 % of NSCLC cases and commands an estimated $1.2 billion U.S. market opportunity. Additionally, the broader biotech sector is benefitting from elevated venture capital inflows and favorable FDA pathways (e.g., accelerated approval) for therapies addressing resistance mechanisms, which can compress time-to-market for candidates like ORIC-114 and ORIC-944.
For a deeper quantitative assessment of ORIC’s valuation and risk profile, you may find it useful to explore the company’s analyst metrics on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -135.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.27 > 0.02 and ΔFCF/TA 9.19 > 1.0 |
| NWC/Revenue: 25.8k% < 20% (prev 16.8k%; Δ 9050 % < -1%) |
| CFO/TA -0.27 > 3% & CFO -116.8m > Net Income -135.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 14.65 > 1.5 & < 3 |
| Outstanding Shares: last quarter (99.0m) vs 12m ago 40.27% < -2% |
| Gross Margin: 14.07% > 18% (prev 0.31%; Δ 1376 % > 0.5%) |
| Asset Turnover: 0.29% > 50% (prev 0.51%; Δ -0.22% > 0%) |
| Interest Coverage Ratio: -26.02 > 6 (EBITDA TTM -139.5m / Interest Expense TTM -5.41m) |
Altman Z'' -15.00
| A: 0.64 (Total Current Assets 295.6m - Total Current Liabilities 20.2m) / Total Assets 431.2m |
| B: -1.53 (Retained Earnings -661.7m / Total Assets 431.2m) |
| C: -0.38 (EBIT TTM -140.7m / Avg Total Assets 366.6m) |
| D: -27.24 (Book Value of Equity -661.1m / Total Liabilities 24.3m) |
| Altman-Z'' Score: -31.99 = D |
What is the price of ORIC shares?
Over the past week, the price has changed by +1.56%, over one month by +28.01%, over three months by -16.97% and over the past year by -16.91%.
Is ORIC a buy, sell or hold?
- StrongBuy: 10
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ORIC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 21 | 101.5% |
| Analysts Target Price | 21 | 101.5% |
| ValueRay Target Price | 10 | -4.4% |
ORIC Fundamental Data Overview February 03, 2026
Revenue TTM = 1.07m USD
EBIT TTM = -140.7m USD
EBITDA TTM = -139.5m USD
Long Term Debt = 3.30m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.30m USD (from shortTermDebt, last quarter)
Debt = 3.30m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -46.4m USD (from netDebt column, last quarter)
Enterprise Value = 715.4m USD (999.2m + Debt 3.30m - CCE 287.1m)
Interest Coverage Ratio = -26.02 (Ebit TTM -140.7m / Interest Expense TTM -5.41m)
EV/FCF = -6.09x (Enterprise Value 715.4m / FCF TTM -117.5m)
FCF Yield = -16.42% (FCF TTM -117.5m / Enterprise Value 715.4m)
FCF Margin = -11.0k% (FCF TTM -117.5m / Revenue TTM 1.07m)
Net Margin = -12.7k% (Net Income TTM -135.3m / Revenue TTM 1.07m)
Gross Margin = 14.07% ((Revenue TTM 1.07m - Cost of Revenue TTM 916.0k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.66 (Enterprise Value 715.4m / Total Assets 431.2m)
Interest Expense / Debt = 60.16% (Interest Expense 1.99m / Debt 3.30m)
Taxrate = 21.0% (US default 21%)
NOPAT = -111.1m (EBIT -140.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 14.65 (Total Current Assets 295.6m / Total Current Liabilities 20.2m)
Debt / Equity = 0.01 (Debt 3.30m / totalStockholderEquity, last quarter 406.9m)
Debt / EBITDA = 0.33 (negative EBITDA) (Net Debt -46.4m / EBITDA -139.5m)
Debt / FCF = 0.39 (negative FCF - burning cash) (Net Debt -46.4m / FCF TTM -117.5m)
Total Stockholder Equity = 298.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -36.90% (Net Income -135.3m / Total Assets 431.2m)
RoE = -45.33% (Net Income TTM -135.3m / Total Stockholder Equity 298.4m)
RoCE = -46.62% (EBIT -140.7m / Capital Employed (Equity 298.4m + L.T.Debt 3.30m))
RoIC = -37.24% (negative operating profit) (NOPAT -111.1m / Invested Capital 298.4m)
WACC = 10.87% (E(999.2m)/V(1.00b) * Re(10.91%) + (debt cost/tax rate unavailable))
Discount Rate = 10.91% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 31.23%
Fair Price DCF = unknown (Cash Flow -117.5m)
EPS Correlation: 68.79 | EPS CAGR: 71.92% | SUE: 4.0 | # QB: 2
Revenue Correlation: 18.10 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.37 | Chg30d=+0.002 | Revisions Net=+2 | Analysts=10
EPS next Year (2026-12-31): EPS=-1.59 | Chg30d=-0.020 | Revisions Net=+0 | Growth EPS=+2.2% | Growth Revenue=+0.0%